Capricor Therapeutics Inc (CAPR.OQ)
CAPR.OQ on NASDAQ Stock Exchange Capital Market
1.33USD
26 Apr 2018
1.33USD
26 Apr 2018
Change (% chg)
$-0.01 (-0.75%)
$-0.01 (-0.75%)
Prev Close
$1.34
$1.34
Open
$1.33
$1.33
Day's High
$1.38
$1.38
Day's Low
$1.32
$1.32
Volume
28,269
28,269
Avg. Vol
67,746
67,746
52-wk High
$4.25
$4.25
52-wk Low
$0.63
$0.63
About
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the... (more)
Overall
| Beta: | -2.65 |
| Market Cap(Mil.): | $67.20 |
| Shares Outstanding(Mil.): | 23.50 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| CAPR.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 84.02 | 32.74 |
| EPS (TTM): | -0.83 | -- | -- |
| ROI: | -645.84 | 1.58 | 14.38 |
| ROE: | -- | 2.41 | 16.07 |
BRIEF-Capricor Q4 Earnings Per Share $0.42
* CAPRICOR PRESENTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE UPDATE
BRIEF-Capricor Therapeutics Says FDA Has Granted CAP-1002 RMAT Designation
* CAPRICOR THERAPEUTICS SAYS FDA HAS GRANTED CAP-1002 REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION - SEC FILING Source text : (http://bit.ly/2s6RQ09) Further company coverage:
BRIEF-Capricor Therapeutics Appoints Anthony Bergmann As CFO, Eff Jan 1, 2018 - SEC Filing
* CAPRICOR THERAPEUTICS INC SAYS HAS APPOINTED ANTHONY BERGMANN AS CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 1, 2018 - SEC FILING
BRIEF-Capricor Therapeutics Says FDA Cleared IND Application For CAP-1002
* CAPRICOR THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CAP-1002
BRIEF-Capricor Therapeutics reports Q3 loss per share $0.12
* Capricor Therapeutics reports third quarter 2017 financial results and provides update on duchenne muscular dystrophy development program
Competitors
| Price | Chg | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $128.01 | +1.25 |
| Novartis AG (NOVN.S) | CHF76.26 | +0.16 |
| Merck & Co., Inc. (MRK.N) | $59.41 | -0.22 |
| Bayer AG (BAYGn.DE) | €98.40 | +1.06 |
| Bayer AG (BAYE.F) | -- | -- |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | 6,150.00 | +13.00 |
| Zealand Pharma Aktieselskabet (ZELA.CO) | kr.94.30 | +2.60 |
| Palatin Technologies, Inc. (PTN.A) | $1.14 | -0.03 |
Estimates